Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
The MHRA agreed that reliance on the substantial body of historic nonclinical and clinical evidence for CBD, alongside legacy data for TMP, provides a scientifically justified basis for a streamlined clinical trial application (CTA)-enabling nonclinical development plan of the cocrystal combination to support the proposed FIH study, with clear guidance for achieving the agreed-upon FIH study design for ART12.11. The agency also affirmed that the proposed first-in-human (FIH) study design—a single-dose, multi-formulation crossover study—was methodologically sound for characterizing ART12.11's pharmacokinetic profile. Importantly, the MHRA offered constructive and specific guidance for completing the data package supporting the agreed-upon Phase 1 trial.
Additionally, the agency proposed that ART12.11 may be a candidate for the Innovative Licensing and Access Pathway (ILAP). ILAP offers a unique opportunity to accelerate the development and patient access of promising new therapies through early and sustained collaboration with the MHRA, National Health Service, and health technology assessment bodies. Given ART12.11's novel mechanism and potential to address unmet needs in anxiety and depression, Artelo believes the program aligns well with ILAP's criteria and will evaluate a formal application to enter the pathway in the coming months.
'It's gratifying to receive this positive feedback and actionable recommendations from the MHRA, which provides a clear path forward as we prepare to initiate clinical studies with ART12.11,' said Dr. Andrew Yates, Chief Scientific Officer at Artelo. 'The recommendation to explore ILAP reinforces the proposition of ART12.11 as a novel drug with the potential to transform the treatment landscape for anxiety and depression.'
Multiple nonclinical studies with ART12.11 have shown its promising profile compared to an antidepressant or CBD alone. The Company recently announced positive preclinical results in a depression model comparing ART12.11 with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), where Artelo's patented CBD:TMP cocrystal demonstrated efficacy on par with sertraline and showed superior cognitive restoration compared to the leading SSRI. Additionally, in a rodent model of stress-induced anxiety and depression, where ART12.11 was compared to CBD dosed at 300% the amount of CBD contained in the oral tablet of ART12.11, the CBD:TMP cocrystal demonstrated efficacy where CBD alone did not.
'The clear regulatory assurance from the regulatory authority in the UK is expected to reduce expenses for our ART12.11 program,' added Gregory Gorgas, President & CEO at Artelo. 'We are especially pleased with the potential for an accelerated development strategy which could greatly accelerate our progress with ART12.11 and could provide for a longer period of market exclusivity as our patents are valid in 20 countries through the end of 2038. Over the next few months we look forward to finalizing our preparations to enter the clinic with ART12.11 early next year.'
About ART12.11
ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Greatly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has now been granted or validated in 19 additional countries.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
'I'm in control of my sexual health' - UK gonorrhoea vaccine rollout begins
Gonorrhoea vaccines will be widely available from today in sexual health clinics across the UK, in a bid to tackle record-breaking levels of infections. The jabs will first be offered to those at highest risk - mostly gay and bisexual men who have a history of multiple sexual partners or sexually transmitted infections. NHS England say the roll out is a world-first, and predict it could prevent as many as 100,000 cases, potentially saving the NHS almost £8m over the next decade. The Terrence Higgins Trust, who campaigned for the vaccine to be introduced in the UK, told the BBC it was "a huge win" for sexual health. Gonorrhoea is a bacterial infection that is transmitted through unprotected sex. Symptoms can include pain, unusual discharge, inflammation of the genitals and infertility, but in some cases it can have no symptoms at all. The NHS says it can be avoided by the proper use of condoms and by accepting the vaccine if offered. Doctors are becoming increasingly worried about the number of infections, and hope the vaccine, which is 30-40% effective, will also help slow the growing number of antibiotic-resistant cases. The vaccine, known as the 4CMenB vaccine, was designed for preventing meningitis B in babies, but the bacteria that causes the two diseases are so closely related that the jab is also effective against gonorrhoea. There were more than 85,000 cases of gonorrhoea in 2023 - the highest since records began almost 100 years ago. One of those diagnosed was Joey Knock, who says the infection gave him diarrhoea, made him feel "wiped out" and led to him taking time off work to recover. He told BBC News: "I discussed it with my friends and I definitely had worse symptoms [than them] with it. "I felt really bad, I couldn't keep food down and I just felt totally run down." Because he has many sexual partners, the 35-year-old decided to pay a private pharmacy for a course of gonorrhoea vaccinations in February 2024 before travelling abroad to a festival. He paid £220 and says he's glad he did it. "It helps knowing that I'm taking control of my sexual health and doing what I can to stay safe and practise safer sex and be much less worried about the severity of the symptoms," he says. Joey says he uses the protection the vaccine offers him alongside other methods of safer sex, including taking PrEP, a drug which helps prevent HIV, and DoxyPep - antibiotics taken after sex to prevent bacterial STIs, a treatment not widely available on the NHS. He says he also occasionally uses condoms - but sees the vaccine as an extra tool to keep him safe in situations where he or his partner doesn't want to use them. Since being vaccinated, Joey has been re-infected with gonorrhoea but says the symptoms were much less severe. He told the BBC: "I've been able to get on with my day and it has just become something much more manageable, and getting tested regularly and knowing my body really helps too." Matthew, a 63-year-old from East Scotland, was diagnosed with gonorrhoea 10 years ago and had a reaction known as reactive arthritis - extreme pain in your joints caused by your body's reaction to an infection. He told the BBC that the experience, which has caused lasting damage to some of his fingers and toes, was so painful it's left him fearful of becoming re-infected and has impacted his mental health. He says: "I'm constantly looking for symptoms and I'm constantly aware of it, and I feel a bit like I used to do in the 1980s when I was constantly fretting about HIV. "I'd get some sort of cough and think 'oh my god, what's happening?'" He is hoping to be one of the first people to get a vaccine in order to give himself and his sexual partners more protection. "You're not just protecting yourself, you're protecting your partners. "I think it will also relieve some of the burden on sexual health services, it's getting difficult to get appointments so if it can work to reduce the incidence of STIs I think it's really worth it." Richard Angell, chief executive of the Terrence Higgins Trust, a leading sexual health charity, told the BBC the vaccine was a "remarkable addition to our toolkit on sexual health". Dr Amanda Doyle, NHS national director for primary care and community services, said it was important "everyone eligible takes up the offer through sexual health services" in order to "keep each other safe". "It's a real step forward for sexual health," she added. People who may be eligible for the vaccine are being asked to contact their local sexual health clinic for more information. Pride in London returns as events struggle with falling funds 'I had a criminal record for 56 years for being a lesbian - nobody told me' 'Our love is frowned upon, but we push through': Navigating religion and relationships
Forbes
12 minutes ago
- Forbes
President Trump's Anti-Growth Agenda Is Harming Families
President Trump loves the phrase promises made, promises kept. Without a major course correction, the President will fail to keep one of his most important promises to the American public – restoring economic prosperity. A post-election analysis from CBS News noted that 'two thirds of voters described the economy as bad, and those voters who did went big for Trump.' Voters trusted Trump over Harris because life had become unaffordable and future economic prospects seemed dim. And consistent with these perceptions, real median household income grew much faster during Trump's first term than during the Biden era. Unfortunately, voters will be severely disappointed based on the policies President Trump is pursuing. There are many examples. Two of the more disconcerting are his obsession with tariffs and his constant berating of U.S. businesses. Starting with the latter, Trump's targeting of the pharmaceutical industry that he consistently refers to as 'Big PhRMA' is troubling – not only for its impact on a major economic anchor for the U.S. economy, but also the precedent it sets for other industries. As I have addressed previously, there are problems with the U.S. drug pricing system that need to be corrected. However, the solution is not threats of price controls. Yet, on July 31st the President 'sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.' Importantly, the President threatened the manufacturers 'that if they 'refuse to step up,' the federal government 'will deploy every tool in our arsenal'' to ensure that the President's will is enforced. These threats are not so veiled references to Trump's Most Favored Nation (MFN) proposal and higher tariffs on imported drugs. The MFN sets the price for a drug at the lowest price charged in other developed countries (OECD), each of which has price controls on drugs. The logic for implementing the MFN is simple – if patients in the U.K., EU, or Canada are paying less money for a drug then so should patients in the U.S. The only reason that the prices for innovative drugs in many OECD countries are lower than the U.S. is because they impose strict price controls and shirk their responsibility for covering the cost of innovation. By forcing these prices here, President Trump is threatening to impose price controls on drugs in the U.S. Making this policy even worse, the Administration consistently complains that 'Europeans are freeloading' and fail to cover their fair share of the costs it takes to create innovative drugs. And he is correct, but the MFN proposal does not end this freeloading. It turns the U.S. into a freeloader. There will be a high cost to patients should the U.S. become just another freeloader that includes diminished drug availability to current patients and reduced hope for new therapies for patients currently living with untreated diseases. Ironically, the policy could even raise total healthcare spending because the reduced drug availability will increase the need for more higher-cost healthcare services such as hospitalizations, surgeries, and emergency department visits. Then there is the signaling problem that arises when the leader of the U.S. government is openly threatening U.S. companies. This jawboning undermines one of our core competitive advantages – a pro-growth business environment grounded in the rule of law. The President's obsession with tariffs – whether on pharmaceuticals, steel, or all imports from a nation – are just as troubling. Tariffs are taxes on U.S. households and businesses. And with the opportunity to stockpile non-tariffed imports over, costs for families are now primed to increase. The tariffs will also raise costs for consumers on domestically produced goods because domestic businesses rely on imports to produce better and more affordable products. As MSNBC reported, 'Procter & Gamble and Walmart are explicitly raising prices because of tariffs.' Small businesses that have smaller margins and less ability to absorb the higher costs are also raising their prices. Facing increased costs, households will be forced to consume less. Particularly noteworthy, given the focus on lowering drug costs discussed above, the tariffs will increase the price of lower-cost generic medicines, which account for 90% of all medicines prescribed annually. Therefore, the President's tariff policies are working at cross purposes to his desire to reduce the costs of medicines for patients. The higher burden from tariffs will not be borne solely by families, domestic manufacturers and retailers of imported goods are also bearing some of these costs. These higher costs reduce the profitability of domestic businesses across a diverse array of industries including automobiles and pharmaceuticals. As the New York Times reported, 'General Motors, Stellantis, Tesla, Mercedes-Benz and Volkswagen have all cited tariffs as one of the main reasons their profits are falling.' The reduced sales and lower profitability is weakening the economy and diminishing employment opportunities – as demonstrated by the latest jobs report that so flustered President Trump. The lower growth environment will subsequently reduce the amount of investment in the U.S. economy. As a result, households across the country will see their earnings growth stagnate while their expenditures on both imported and domestically produced products will increase. Whether through trade or regulatory policies, the Trump Administration is pursuing a decidedly anti-growth policy agenda. The results are completely expected – a weaker economy with slower job growth and diminishing opportunities for families across the country. These outcomes break the fundamental promise that candidate Trump made while running for president – to restore prosperity.
Yahoo
40 minutes ago
- Yahoo
Terra Firma Energy Limited Announces Successful Completion of Initial 6 Months Commercial Operation at Miners Road, Wrexham, Flexible Generation Site
LONDON, August 04, 2025--(BUSINESS WIRE)--Terra Firma Energy Limited (TFE) is delighted to announce that its 20.7MW Miners Road flexible generation site, located in Llay, Wrexham, United Kingdom, has successfully completed its first 6 months of commercial operations. The significant 6-month milestone has been achieved through the collective efforts of TFE's trusted partners. Blackstone Energy played a pivotal role in the development and delivery of the project, while Finning CAT provided the advanced hydrogen-ready generators that are critical to the site's success. The energy team at Close Brothers Asset Finance supported the project's financial structuring, enabling the realisation of this addition to the UK's energy infrastructure. Together, these partners have helped develop Miners Road into a fully operational facility now strengthening the local grid and meeting the UK's evolving energy demands. About Flexible Generation Plants Flexible power generation is crucial to maintaining grid stability and ensuring reliable energy supply in the UK. With the Miners Road site now operational, the focus shifts to Terra Firma Energy's long term optimisation partner, EDF (UK). Using their expertise, EDF have integrated the asset into the UK's wholesale and ancillary service markets, enabling it to provide secure and flexible power exactly when and where it's needed. This dynamic approach ensures that the facility not only enhances local energy resilience but also contributes to the nation's broader energy transition goals by complementing the variability of renewable energy sources. William Davies, Managing Director of Terra Firma Energy, commented: "Having successfully completed 6 months of commercial operation our Miners Road project is a testament to the collaborative efforts of our exceptional partners and the strength of our shared commitment to a sustainable energy future. With the baton passed to EDF (UK), our optimiser for the asset, we are confident that this site will play a vital role in providing flexible power solutions for the UK." For more news from Terra Firma Energy please click here Notes to Editors About Terra Firma Energy Limited Terra Firma Energy Limited are a privately owned U.K. based company operating in the development of renewable & sustainable energy projects. We design, develop & construct carefully sourced projects with the emphasis on making them a cleaner & more respectful source of energy production for future generations. Website - Home - Terra Firma Energy LinkedIn - YouTube - Facebook - Instagram - X - View source version on Contacts Terra Firma Energy LimitedHelen AletrasHead of PR and +44 (0)203 890
